Tuesday, Citi initiated coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a $609 million market cap company, with a Buy rating and a price target of $33.00. The stock, which has gained over 16% in the past week, is currently trading below its InvestingPro Fair Value. The firm's analysis draws parallels between EyePoint's development of sustained-release drugs for wet age-related macular degeneration (wAMD) and previous competitive races in the ophthalmology sector that significantly progressed treatment standards.
The Citi analysts anticipate that EyePoint Pharmaceuticals and its main competitor, OCUL, will both secure substantial market share in the wAMD treatment space. According to InvestingPro data, analysts are notably bullish on EYPT, with price targets ranging from $18 to $68, suggesting significant upside potential. They predict that one of the two is likely to emerge as the dominant force in the long run. While the final outcome is contingent on phase 3 data expected in the fourth quarter of 2025 for OCUL and in 2026 for EyePoint, current insights offer some early predictions.
A recent survey conducted in December 2024, which included approximately 100 physicians, indicated a preference for EyePoint's efficacy data. The survey results showed that EyePoint's data might be more compelling due to a significantly larger sample size in their study compared to OCUL (102 vs. 15). Despite phase 3 trial endpoints seemingly favoring OCUL, Citi analysts highlighted that there are crucial nuances to consider.
The analysts also noted potential differences in potency and delivery/formulation that suggest the real-world differentiation between the two companies' products will not solely depend on the debates currently taking place among investors. The initiation of a Buy rating with a high-risk designation reflects the firm's optimistic stance on EyePoint's market potential balanced with the acknowledgment of the uncertainties that lie ahead.
InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 5.5 and more cash than debt on its balance sheet, though it's currently unprofitable with negative earnings. Subscribers can access 8 additional ProTips and comprehensive financial metrics in the Pro Research Report.
In other recent news, EyePoint Pharmaceuticals has achieved significant advancements in its clinical trials and financial operations. The biotechnology company has initiated the LUCIA trial, a second global Phase 3 clinical study for its investigational drug DURAVYU, aimed at treating wet age-related macular degeneration (wet AMD (NASDAQ:AMD)). The first patient in the trial has been dosed, highlighting the company's commitment to addressing severe retinal diseases.
EyePoint's recent financial activities include reporting a net revenue of $10.5 million and a net loss of $29.4 million for the third quarter, and initiating a public offering of its common stock valued at $100 million. These strategic moves aim to extend the company's cash runway into 2027.
Analysts from Baird, H.C. Wainwright, Guggenheim, Laidlaw, and CapitalOne have provided varied outlooks on the company. Baird and H.C. Wainwright have maintained their Outperform and Buy ratings respectively, but reduced their price targets, while Guggenheim and Laidlaw have reiterated their Buy ratings. CapitalOne, however, has kept its Underweight rating.
EyePoint anticipates topline data from the Phase 3 pivotal trials in 2026 and from a Phase 2 trial in diabetic macular edema in the first quarter of 2025. The company has also seen changes to its board with the appointment of Fred Hassan and the resignations of Anthony P. Adamis, M.D., and David Guyer, M.D.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.